DarioHealth Q4 Revenue Forecast at $5.05M, Price Target Implies 128% Upside
DarioHealth is forecast to post Q4 2025 revenue of $5.05M and EPS of -$4.16, with full-year sales seen at $22.18M and EPS at -$2.92. Over 90 days, 2026 revenue estimates were cut from $28.72M to $25.76M while analysts peg a $20 average price target implying 128.6% upside.
1. Q4 and Full-Year Forecasts
DarioHealth is expected to report Q4 2025 revenue of $5.05 million and a loss per share of $4.16, bringing full-year 2025 revenue to an estimated $22.18 million with EPS at -$2.92. These projections follow a prior quarter where revenue fell short by 11.6% but EPS outperformed by nearly 32%.
2. Estimate Revisions
Over the past 90 days, full-year 2025 revenue estimates dipped from $22.29 million to $22.18 million, while 2026 revenue forecasts were trimmed more sharply from $28.72 million to $25.76 million. Earnings per share for 2026 remain pegged at a loss of $15.75, reflecting ongoing margin pressures.
3. Price Targets and Ratings
Analysts’ average one-year price target stands at $20.00, ranging from $11.00 to $28.00 and implying a 128.6% upside. Brokerages assign an average recommendation rating of 2.0, signaling an Outperform view on the company.